Design Therapeutics, Inc.
DSGN

$367.47 M
Marketcap
$6.49
Share price
Country
$-0.29
Change (1 day)
$7.77
Year High
$2.25
Year Low
Categories

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

marketcap

Stock price history for Design Therapeutics, Inc. (DSGN)

Highest end of day price: $41.49 USD on 2021-03-26

Lowest end of day price: $1.99 USD on 2023-11-09

Stock price history of Design Therapeutics, Inc. from 2021 to 2024